{
  "source": "PA-Med-Nec-Tezspire.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2309-2\nProgram Prior Authorization/Medical Necessity\nMedications Tezspire™ (tezepelumab-ekko)*\n*This program applies to the prefilled pen for self-administration\nP&T Approval Date 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nTezspire (tezepelumab) is indicated for the add-on maintenance treatment of adult and pediatric\npatients aged 12 years and older with severe asthma.\nLimitations of use:\nTezspire is not indicated for relief of acute bronchospasm of status asthmaticus.\n2. Coverage Criteriaa:\nA. Severe Asthma\n1. Initial Authorization\na. Tezspire will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Patient has been established on therapy with Tezspire under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nsevere asthma\n-AND-\n(b) Documentation of positive clinical response to Tezspire therapy as\ndemonstrated by at least one of the following:\ni. Reduction in the frequency of exacerbations\nii. Decreased utilization of rescue medications\niii. Increase in percent predicted FEV1 from pretreatment baseline\niv. Reduction in severity or frequency of asthma-related symptoms (e.g.,\nwheezing, shortness of breath, coughing, etc.)\n-AND-\n(c) Tezspire is being used in combination with an inhaled corticosteroid (ICS)-\ncontaining controller medication [e.g., Advair/AirDuo Respiclick\n(fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol),\nBreo Ellipta (fluticasone furoate/vilanterol), Trelegy Ellipta (fluticasone\n© 2024 UnitedHealthcare Services, Inc.\n1\nfuroate/umeclidinium/vilanterol)]\n-AND-\n(d) Patient is not receiving Tezspire in combination with any of the following:\ni. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab), Nucala (mepolizumab)]\nii. Anti-IgE-therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\n-AND-\n(e) Prescribed by one of the ",
    "izumab), Fasenra\n(benralizumab), Nucala (mepolizumab)]\nii. Anti-IgE-therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\n-AND-\n(e) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Pulmonologist\n-OR-\n(2) All of the following:\n(a) Diagnosis of severe asthma\n-AND-\n(b) Classification of asthma as uncontrolled or inadequately controlled as\ndefined by at least one of the following:\ni. Poor symptom control (e.g., Asthma Control Questionnaire [ACQ]\nscore consistently greater than 1.5 or Asthma Control Test [ACT] score\nconsistently less than 20)\nii. Two or more bursts of systemic corticosteroids for at least 3 days each\nin the previous 12 months\niii. Asthma-related emergency treatment (e.g., emergency room visit,\nhospital admission, or unscheduled physician’s office visit for nebulizer\nor other urgent treatment)\niv. Airflow limitation (e.g., after appropriate bronchodilator withhold\nforced expiratory volume in 1 second [FEV1] less than 80% predicted\n[in the face of reduced FEV1/forced vital capacity [FVC] defined as\nless than the lower limit of normal])\nv. Patient is currently dependent on oral corticosteroids for the treatment\nof asthma\n-AND-\n(c) Tezspire will be used in combination with one of the following:\ni. One maximally dosed (appropriately adjusted for age) combination\n© 2024 UnitedHealthcare Services, Inc.\n2\ninhaled corticosteroid (ICS)/long-acting beta agonist (LABA) product\n2\n[e.g., Advair/AirDuo Respiclick (fluticasone propionate/salmeterol),\nSymbicort (budesonide/formoterol), Breo Ellipta (fluticasone\nfuroate/vilanterol)]\n-OR-\nii. Combination therapy including both of the following:\n• One maximally dosed (appropriately adjusted for age) ICS product\n[e.g., ciclesonide (Alvesco), mometasone furoate (Asmanex),\nbeclomethasone dipropionate (QVAR)]\n-AND-\n• One additional asthma controller medication [e.g., LABA -\nolodaterol (Striverdi) or indacaterol (Arcapta); leukotriene receptor\nantagonist – monteluk",
    "anex),\nbeclomethasone dipropionate (QVAR)]\n-AND-\n• One additional asthma controller medication [e.g., LABA -\nolodaterol (Striverdi) or indacaterol (Arcapta); leukotriene receptor\nantagonist – montelukast (Singulair); theophylline]\n-AND-\n(d) Patient is not receiving Tezspire in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab), Nucala (mepolizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\n-AND-\n(e) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Pulmonologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tezspire will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Tezspire therapy as demonstrated\nby at least one of the following:\n(a) Reduction in the frequency of exacerbations\n(b) Decreased utilization of rescue medications\n(c) Increase in percent predicted FEV1 from pretreatment baseline\n(d) Reduction in severity or frequency of asthma-related symptoms (e.g.,\nwheezing, shortness of breath, coughing, etc.)\n© 2024 UnitedHealthcare Services, Inc.\n3\n-AND-\n(2) Tezspire is being used in combination with an ICS-containing controller\nmedication [e.g., Advair/AirDuo Respiclick (fluticasone propionate/salmeterol),\nSymbicort (budesonide/formoterol), Breo Ellipta (fluticasone\nfuroate/vilanterol), Trelegy Ellipta (fluticasone\nfuroate/umeclidinium/vilanterol)]\n-AND-\n(3) Patient is not receiving Tezspire in combination with any of the following:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab), Nucala (mepolizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. O",
    "pilumab)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limitations may be in place.\n• The single-dose vial and pre-filled syringe for administration by a healthcare professional is\ntypically covered under the medical benefit. Please refer to the United Healthcare Medical\nBenefit Drug Policy: “Tezspire™ (tezepelumab-ekko).”\n4. References:\n1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023.\nAvailable at http://www.ginasthma.org. Accessed May 29, 2024.\n2. Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma\nphenotypes in a general population with current asthma. Ann Allergy Asthma Immunol.\n2016;116(1):37-42. doi:10.1016/j.anai.2015.10.027.\n3. Corren J, Ziegler SF. TSLP: from allergy to cancer. Nat Immunol. 2019;20(12):1603-1609.\ndoi:10.1038/s41590-019-0524-9.\n4. Tezspire™ [package insert]. Thousand Oakes, CA: Amgen Inc.; May 2023.\n5. Institute for Clinical and Economic Review (ICER). Tezepelumab for Severe Asthma.\nNovember 4, 2021. Available at ICER | Working Towards Fair Pricing, Fair Access, &\nFuture Innovation. Accessed May 29, 2024.\n6. Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer\nL, Khurana S, Knight S, McDonald VM, Morgan RL, Ortega VE, Rigau D, Subbarao P,\n© 2024 UnitedHealthcare Services, Inc.\n4\nTonia T, Adcock IM, Bleecker ER, Brightling C, Boulet LP, Cabana M, Castro M, Chanez P,\nCustovic A, Djukanovic R, Frey U, ",
    " RL, Ortega VE, Rigau D, Subbarao P,\n© 2024 UnitedHealthcare Services, Inc.\n4\nTonia T, Adcock IM, Bleecker ER, Brightling C, Boulet LP, Cabana M, Castro M, Chanez P,\nCustovic A, Djukanovic R, Frey U, Frankemölle B, Gibson P, Hamerlijnck D, Jarjour N,\nKonno S, Shen H, Vitary C, Bush A. Management of severe asthma: a European Respiratory\nSociety/American Thoracic Society guideline. Eur Respir J. 2020 Jan 2;55(1):1900588. doi:\n10.1183/13993003.00588-2019. PMID: 31558662\nProgram Prior Authorization/Medical Necessity - Tezspire (tezepelumab)\nChange Control\n7/2023 New program.\n7/2024 Annual review. Modified criteria for existing prior authorization for\nunder the medical benefit. Removed footnote disclaimer for step\ntherapy. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}